MRD Assessment Gains Momentum in Hematologic Malignancies
Published: Friday, Apr 03, 2020
Jerald P. Radich, MD
Measurable residual disease (MRD) serves as an important biomarker to determine how a patient with a hematologic malignancy is responding to treatment, according to Jerald P. Radich, MD.
... to read the full story